Study to Evaluate CCS1477 in Advanced Tumors

Inclusion Criteria

• Must provide consent to participate.
• Be in good general health with an ECOG performance status of 0 or 1, meaning fully active or restricted in physically strenuous activity but ambulatory.
• Have cancer that can be measured using scans or X-rays.
• Have good organ function as determined by medical tests.
• Use highly effective birth control during the study.

Additional criteria for prostate cancer patients:

• Previously treated with specific prostate cancer drugs like abiraterone or enzalutamide, and possibly docetaxel.
• Cancer must be progressing, shown by rising PSA levels, new bone lesions, or other criteria.
• PSA level at screening must be 2 μg/L or higher.
• Low testosterone levels (≤50 ng/dL).
• Serum albumin level greater than 2.5 g/dL.

For patients in the CCS1477 plus abiraterone group:

• Must have cancer that progressed on abiraterone.
• If last abiraterone dose was over 6 months ago, a 4-week trial of abiraterone is needed to confirm it no longer works.

For patients in the CCS1477 plus enzalutamide group:

• Must have cancer that progressed on enzalutamide.
• If last enzalutamide dose was over 6 months ago, a 4-week trial of enzalutamide is needed to confirm it no longer works.

For patients in the mutation group:

• Have advanced solid tumors with specific genetic markers that may respond to the treatment.

Exclusion Criteria

• Have received chemotherapy or other cancer treatments within 14 days or 5 half-lives before starting the study.
• Have had major surgery or significant injury within 4 weeks before starting the study.
• Have taken certain medications that affect the liver enzyme CYP3A4 within 2 to 4 weeks before starting the study.
• Have unresolved side effects from previous treatments that are more than mild.
• Have severe or uncontrolled diseases or illnesses.
• Have a prolonged QT interval on an ECG (>480 milliseconds).
• Have primary brain tumors or known/suspected brain metastases.

Additional criteria for the CCS1477 plus abiraterone group:

• Have significant heart problems.

Additional criteria for the CCS1477 plus enzalutamide group:

• Have a history of seizures or factors that increase seizure risk.
• Have taken certain medications that are metabolized by CYP2C9 or CYP2C19 within 2 weeks before starting the study.
• Have significant heart problems.